Harmony Biosciences Holdings Inc

For the period ended Dec 31, 2024. Filed Feb 25, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 25, 2025

HRMY$33.78+2.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

	Page
Part I	3
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	3
ITEM 1. BUSINESS.	5
ITEM 1A. RISK FACTORS.	26
ITEM 1B. UNRESOLVED STAFF COMMENTS.	71
ITEM 1C. CYBERSECURITY	71
ITEM 2. PROPERTIES.	74
ITEM 3. LEGAL PROCEEDINGS.	74
ITEM 4. MINE SAFETY DISCLOSURES.	74
Part II	75
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.	75
ITEM 6: [RESERVED]	76
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	76
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	88
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.	88
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.	117
ITEM 9A. CONTROLS AND PROCEDURES.	117
ITEM 9B. OTHER INFORMATION.	119
ITEM 9C. DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS	119
Part III	120
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.	120
ITEM 11. EXECUTIVE COMPENSATION.	120
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.	120
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.	120
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.	120
Part IV	121
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.	121
SIGNATURES	124

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents